Endo International Q3 revenues 14 percent betterStaff writer ▼ | November 6, 2015
Endo International reported third quarter 2015 financial results. Revenues were $746 million, a 14 percent increase compared to Q3 2014 revenues of $654 million, including new product revenue from 2014 and 2015 strategic M&A transactions.
Endo International Q3 revenues were $746 million
Reported diluted loss per share from continuing operations of $3.84 compared to third quarter 2014 reported diluted earnings per share from continuing operations of $0.31.
Adjusted income from continuing operations of $214 million, a 31 percent increase compared to third quarter 2014 adjusted income from continuing operations of $163 million.
Adjusted diluted earnings per share from continuing operations of $1.02 compared to third quarter 2014 adjusted diluted earnings per share from continuing operations of $1.03.
"Our diversified business delivered solid financial results this quarter and was further strengthened by our completed acquisition of Par Pharmaceutical Holdings.
"As we continue to execute on our strategy of organic growth, de-risked pipeline development and creating shareholder value through accretive, strategic M&A, we believe Endo is positioned for overall double-digit revenue expansion over the mid- to long-term," said Rajiv De Silva, president and CEO of Endo.
"Fundamentally, our business is more diversified and well positioned financially and strategically. Following the recent FDA approval of BELBUCA, we are conducting a strategic portfolio optimization process to expand our pain sales force and reallocate resources across key growth products in our U.S. Branded Pharmaceuticals business.
"Moving forward, we remain focused on execution and value creation activities: the integration of Par, driving growth for our priority branded products, growing our international presence and strategic M&A." ■